AGL: Investors Who Lost Money In Agilon Health Stock Should Contact Block & Leviton By March 2nd To Potentially Recover Losses

Core Viewpoint - A securities fraud lawsuit has been filed against Agilon Health, Inc. (NYSE: AGL) following a significant drop in its stock price after the resignation of its CEO and the withdrawal of its financial guidance for 2025 [1][2]. Group 1: Company Developments - Agilon Health's shares fell over 25% in after-hours trading on August 4, 2025, due to the unexpected resignation of CEO Steven Sell and the withdrawal of the company's full-year 2025 financial guidance, attributed to unforeseen medical cost pressures and downward revenue adjustments [2]. - The lawsuit alleges that Agilon Health issued guidance for 2025 that was knowingly unattainable, given the material industry challenges they were aware of, and that they overstated the financial benefits from strategic actions taken to mitigate risks [3]. Group 2: Investor Information - Investors who purchased Agilon Health common stock between February 26, 2025, and August 4, 2025, and experienced a decline in their shares may be eligible to participate in the lawsuit, regardless of whether they sold their investment [4]. - The deadline for seeking appointment as lead plaintiff in the lawsuit is March 2, 2026, and a class has not yet been certified, meaning potential participants are not yet represented by an attorney [5]. Group 3: Whistleblower Information - Individuals with non-public information about Agilon Health are encouraged to assist in the investigation or file a report with the SEC under the whistleblower program, which offers rewards of up to 30% of any successful recovery [6]. Group 4: Legal Representation - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].